News
05-03-2010, 09:01 AM
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 was administered at much higher doses.
More... (http://www.news-medical.net/news/20100503/Interim-study-results-demonstrate-anti-tumor-activity-of-CytRxs-INNO-206-in-myeloma-tumor-cells.aspx)
More... (http://www.news-medical.net/news/20100503/Interim-study-results-demonstrate-anti-tumor-activity-of-CytRxs-INNO-206-in-myeloma-tumor-cells.aspx)